Phase 1b/2a clinical trial in adults of novel TB vaccine candidate MTBVAC shows promising results.

NEW YORK, USA, PORRIÑO, SPAIN, CAPE TOWN, SOUTH AFRICA – April 22, 2025 : IAVI, Biofabri, the University of Zaragoza (UNIZAR), and the South African Tuberculosis Vaccine Initiative (SATVI) are pleased to announce today promising results from the IAVI-sponsored A-050 Phase 1b/2a clinical trial testing a novel tuberculosis (TB) vaccine candidate, MTBVAC.

Findings from IAVI A-050, published April 15, 2025 in Lancet Global Health, demonstrate that vaccination with MTBVAC caused similar or stronger immune responses compared to the Bacille Calmette-Guérin (BCG) vaccine in adults, and that different doses of MTBVAC were as safe as BCG. The century-old BCG vaccine is the only available TB vaccine and has proven to be ineffective in controlling the spread of TB among adolescents and adults, among whom 90% of TB transmission and disease occurs. 

Resources:

Press release: IAVI, Biofabri and SATVI. Click here

Research Article. Click here